A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Study to Assess the Efficacy and Safety of Methyl aminolevulinate hydrochloride (MAL) 16.8% cream (CD06809-41) versus vehicle cream in the treatment of thin and moderately thick, non-hyperkeratotic, non-pigmented actinic keratosis of the face and scalp when using daylight photodynamic therapy (DL-PDT).
This was a randomized, double-blind, vehicle-controlled, multicenter, parallel-group study in adult participants with clinically-confirmed mild to moderate AKs on the face and the balding scalp, to be conducted at approximately 60 clinical sites in the United States. Sites were selected to ensure that diverse daylight conditions represented in the study to understand the effects of latitude, elevation, and climate.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
557
Day light photodynamic therapy with MAL 16.8% cream
Day light photodynamic therapy with MAL vehicle cream
Percentage of Participants With Complete Response at Week 12
Complete response was defined as clearance of all AK lesion treated, at week 12 after the last Daylight photodynamic therapy (DL-PDT).
Time frame: Week 12
Percent Change From Baseline in Lesion Complete Response at Week 12
Lesion complete response was defined as percent reduction from baseline in the number of cleared treated lesions, at 12 weeks after the last DL-PDT treatment. This outcome measure was analyzed as an intra-individual comparison between MAL cream and Vehicle cream.
Time frame: Baseline, Week 12
Percentage of Participants With Partial Response at Week 12
Participants achieving partial response was defined as participants with 75% or greater reduction from baseline in the number of cleared treated lesions, at 12 weeks after the last DL-PDT treatment, comparing MAL cream with vehicle cream.
Time frame: Week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Galderma Investigational Site (Site 8768)
Tucson, Arizona, United States
Galderma Investigational Site (Site 8447)
Fort Smith, Arkansas, United States
Galderma Investigational Site (Site 8577)
Encinitas, California, United States
Galderma Investigational Site (Site 8636)
Fountain Valley, California, United States
Galderma Investigational Site (Site 8224)
Fremont, California, United States
Galderma Investigational Site (Site 8114)
Fresno, California, United States
Galderma Investigational Site (Site 8758)
San Diego, California, United States
Galderma Investigational Site (Site 8608)
Santa Monica, California, United States
Galderma Investigational Site (Site 8778)
Denver, Colorado, United States
Galderma Investigational Site (Site 8440)
Greenwood Village, Colorado, United States
...and 50 more locations